Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Forsyth, CA

Allyn Forsyth, San Diego, CA US

Patent application numberDescriptionPublished
20090215088Tagged Ligands For Enrichment of Rare Analytes From A Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.08-27-2009
20110300603Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.12-08-2011

Ben Forsyth, San Francisco, CA US

Patent application numberDescriptionPublished
20110145810METHOD IN A NETWORK OF THE DELIVERY OF FILES - A method in a network of the delivery of files from a server computer (06-16-2011

David E. Forsyth, Laguna Beach, CA US

Patent application numberDescriptionPublished
20090188501Self Contained Breathing Apparatus Modular Control System - The claim over prior art is for an approach to an electronically controlled or electronically monitored breathing system that represents an improvement in electrical reliability, manufacturing cost and efficiency, user maintenance, system reliability, user cost and maintenance. These improvements are accomplished by placing the major electronic, mechanical and electromechanical control elements and sensor components in a single replaceable module.07-30-2009

David Edward Forsyth, Laguna Beach, CA US

Patent application numberDescriptionPublished
20120078532NON-DISPERSIVE INFRARED SENSOR MEASUREMENT SYSTEM AND METHOD - Non-dispersive infrared (NDIR) sensing systems employ a NDIR sensor coupled to a microprocessor to determine gas concentrations by employing slope-based methodologies that compensate for pressure variations, temperature variations, or both, which may compare NDIR signals with calibrated data. NDIR sensor systems may employ means for limiting the system peak current demand providing for the portability and scalability of the system. In NDIR sensor systems calculating gas concentrations using calibration data, the phase of the change in the NDIR output signal in response to a change in the infrared source emitter level may be measured as part of the calibration process.03-29-2012

Roger Allyn Forsyth, San Diego, CA US

Patent application numberDescriptionPublished
20100120047PURIFICATION OF TARGET CELLS FROM COMPLEX BIOLOGICAL FLUIDS - A method for conducting a molecular analysis on target cells of a complex biological fluid can include the steps of reducing the complexity by selectively depleting at least a portion of non-target cells from the biological fluid, labeling target cells or non-target cells for identification, isolating target cells from non-target cells based on (i) a size, or (ii) a label, of the target cells or the non-target cells using a microfluidic sorting apparatus, and molecularly analyzing the target cells. Reducing can include separating the non-target cells from the biological fluid using a Magnetic Activated Cell Sorting apparatus or using magnetic beads that include a plurality of different antibodies including one or more of CD45, CD16 and 235a. Labeling can include using a label selected from fluorescent, colorimetric, magnetic and biochemical labels. The biological fluid can be selected from blood sputum, peritoneal fluid, tissue cell suspension, fine needle aspirates, fecal matter and cerebral spinal fluid. The target cells can be selected from tumor cells, fetal cells, stem cells, endothelial cells, myocardial cells and lymphocytes. The step of molecularly analyzing the target cells can include one of RNA analysis, antigen expression and mutation profiling.05-13-2010

Timothy Forsyth, Hayward, CA US

Patent application numberDescriptionPublished
20100136136JAK-2 Modulators and Methods of Use - This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.06-03-2010

Timothy Patrick Forsyth, Hayward, CA US

Patent application numberDescriptionPublished
20080234270Pyrrole Derivatives As Pharmaceutical Agents - Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.09-25-2008
20080249079Pyrimidine Derivatives As Kinase Modulators and Method of Use - The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR10-09-2008
20090105211INHIBITORS OF HEDGEHOG PATHWAY - The present invention is directed to a compound of Formula I04-23-2009
20090105299c-MET MODULATORS AND METHODS OF USE - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.04-23-2009
20090170896c-Met modulators and methods of use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.07-02-2009
200902988304-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use - This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R12-03-2009
20110077233C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.03-31-2011
20110201599CDK Modulators - A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.08-18-2011
20110301128Pyrrole Derivatives As Pharmaceutical Agents - Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.12-08-2011
20120022065C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.01-26-2012
20120070368Methods of Using C-Met Modulators - Disclosed are methods of treating cancer by administering a compound of Formula I,03-22-2012

Patent applications by Timothy Patrick Forsyth, Hayward, CA US